Poster Spotlight 13: Focus on CNS

Moderator

Carey K. Anders, Duke University, Durham, NC

Presentation numberPD13-01

Site(s) of Distant Recurrence after Neoadjuvant Therapy for Patients With High-Risk Early-Stage Breast Cancer (BC): Analysis of Data from the I-SPY2 Trial

Laura Huppert, University of California, San Francisco, San Francisco, CA

Presentation numberPD13-02

Cytomegalovirus reactivation drives brain metastasis in breast cancer via immunosuppressive microglial reprogramming

Wenjuan Dong, Houston Methodist Research Institute, Houston, TX

Presentation numberPD13-03

Clinical and pathological variables associated with brain metastases (BrM) development among patients receiving neoadjuvant chemotherapy (NAC) for breast cancer (BC)

Italo Fernandes, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Presentation numberPD13-04

Rhenium (186Re) obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Phase 1 dose escalation study results

Andrew Brenner, University of Texas Health Science Center at San Antonio, San Antonio, TX

Presentation numberPD13-05

Clinical-pathological patterns and prognosis of young women with breast cancer brain metastases: a single-centre retrospective study

Isabella Kojundzic, University of Toronto, Toronto, ON, Canada

Presentation numberPD13-06

Discussant: Clinical Patterns and Novel Therapeutics

Sasha Beyer, Ohio State University Wexner Medical Center, Columbus, OH

Presentation numberPD13-07

A transcriptomic analysis of a first in human phase I trial of intrathecal dendritic cells (cDC1s) in patients with leptomeningeal disease (LMD) shows development of an adaptive immune response and very long survival in LMD

Peter Forsyth, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Presentation numberPD13-08

Radiation Therapy Followed by Intrathecal (IT) Trastuzumab/Pertuzumab in the Management of HER2⁺ Breast Leptomeningeal Disease: Interim Results from a Phase II Multi-Institutional Study

Kamran Ahmed, Moffitt Cancer Center, Tampa, FL

Presentation numberPD13-09

A Real-World Multicenter Study in China: Efficacy and Safety of Sacituzumab Govitecan in Heavily Pretreated HER2-Negative Metastatic Breast Cancer Patients and Brain Metastases

Xu Liang, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),Peking University Cancer Hospital & Institute, Beijing, China

Presentation numberPD13-10

Outcome of patritumab deruxtecan (HER3-DXd) in patients with HER2-positive metastatic breast cancer and CNS involvement previously treated with T-DXd: A subanalysis of TUXEDO-3

Rupert Bartsch, Medical University of Vienna, Vienna, Austria

Presentation numberPD13-11

Interim analysis results for the effectiveness and safety of trastuzumab deruxtecan in patients with HER2-low breast cancer and brain metastases: The HALLOW study

Naoki Niikura, Tokai University School of Medicine, Tokyo, Japan

Presentation numberPD13-12

Discussant: Treatment Strategies and Outcomes

Sarah L. Sammons, Dana-Farber Cancer Institute, Boston, MA